Devonian Health Group has appointed Dennis Turpin as Chief Financial Officer. This transition follows key updates on stock options and a commitment to innovative health solutions.

Devonian Health Group Inc. announces its upcoming listing on NYSE American, expected to bolster its market presence and brand recognition.

Devonian Health Group Inc. has upgraded its manufacturing platform for Thykamine™ through validated analytical techniques, enhancing product consistency and quality control.

Devonian Health Group Inc. is set to start trading on the NYSE American soon, following an underwritten public offering, with trading expected to begin by August 21, 2026.

Devonian Health Group has secured permission from Health Canada to start a Phase II/III clinical trial on Thykamine™, targeting mild-to-moderate atopic dermatitis in children aged 3 months to 17 years. The study aims to evaluate efficacy and safety.

Devonian Health Group recently held its Annual Meeting of Shareholders, where significant corporate governance changes were approved, emphasizing future growth.

Devonian Health Group Inc. reveals its financial outcomes for the quarter and six-month period ending January 31, 2026, highlighting new strategies and clinical advancements.

Devonian Health Group has reported promising findings from a study on Thykamine™, showing its effects on metabolic-associated steatohepatitis through innovative liver-on-a-chip technology.

Devonian's recent findings on Thykamine™ provide critical insights into its anti-inflammatory effects on liver diseases, enhancing our understanding of metabolic dysfunction.

Devonian Health Group Inc. has announced a significant grant of stock options to its board members and employees, aiming to boost their performance and retention.

Devonian Health Group has revealed its fourth quarter and annual financial results for 2025, highlighting significant developments including a new board member appointment.